Irisin vs Insulin Glargine
Head-to-head comparison of Irisin (Irisin (FNDC5 cleavage product)) and Insulin Glargine (Insulin glargine (A21Gly,B31Arg,B32Arg human insulin analog)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Irisin | Insulin Glargine |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Irisin (FNDC5 cleavage product) | Insulin glargine (A21Gly,B31Arg,B32Arg human insulin analog) |
| Molecular Weight | ~12.3 kDa | 6063.6 Da |
| Half-Life | hours | About 12-24 hours |
| Amino Acids | 112 | 51 |
| Typical Dose | No approved human dose; research use only | 0.1-0.2 U/kg once daily |
| Route | IV|SC | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 79 | 13000 |
| Research Status | Pre-clinical | Approved |
Irisin Benefits
- ✓glucose homeostasis
- ✓energy expenditure
- ✓brown-fat activation
Insulin Glargine Benefits
- ✓Once-daily basal coverage
- ✓Smooth action profile
- ✓Lower nocturnal hypoglycemia risk
- ✓Improves fasting glucose control
Irisin Dosing
not established|not established
Insulin Glargine Dosing
Inject SC once daily at the same time each day|Titrate every 3-4 days to fasting glucose targets|Can be combined with prandial insulin
Irisin Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Insulin Glargine Side Effects
- ⚠Hypoglycemia
- ⚠Injection-site reactions
- ⚠Weight gain
Research Overview
Irisin
Irisin is widely explored in obesity and type 2 diabetes research because it connects exercise biology with metabolic adaptation. Human findings are mixed, so it remains a biomarker and preclinical lead rather than an approved therapy.
Insulin Glargine
Clinical and translational studies support its use as a basal comparator because of prolonged absorption and stable glycemic control. It is heavily used in basal-bolus regimen research and insulin-delivery optimization studies.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.